Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity

Jonathan C. Javitt, Gergana P. Zlateva, Stephanie R. Earnshaw, Andreas M. Pleil, Christopher N. Graham, Anita J. Brogan, Sonali N. Shah, Anthony P. Adamis

Research output: Contribution to journalArticle

Abstract

Objective: To compare the cost-effectiveness of pegaptanib and usual care within three distinct cohorts of subfoveal neovascular age-related macular degeneration (NV-AMD) patients, that is, those with early, moderate, and late disease, using a comprehensive economic model. Methods: A Markov framework was used to model lifetime movement of a subfoveal NV-AMD cohort through health states based on visual acuity. The model takes a US payer perspective of patients over the age of 65 years. Clinical efficacy was based on published results for the 0.3 mg pegaptanib and usual care groups. Expert interviews were conducted to determine adverse event treatment patterns and vision rehabilitation resource use. Incidence and costs of comorbidities such as depression and fractures associated with the effects of declining visual acuity were based on our previously published analysis of Medicare data. Transition probabilities were derived from published clinical trial data for each 3-month cycle. Utilities were derived from published sources. Three runs of the model were conducted with cohorts of newly diagnosed patients. Patients were classified as having early, moderate, or late NV-AMD defined as visual acuity in the better-seeing eye of 20/40 to more than 20/80, 20/80 to more than 20/200, and 20/200 to more than 20/400, respectively. Costs and outcomes were discounted 3.0% per annum. Results: Incremental costs per vision-year gained and per quality-adjusted life-year (QALY) gained for early NV-AMD patients were approximately one-third those of patients with late disease ($15,279 vs. $57,230 and $36,282 vs. $132,381, respectively). On average, patients treated early with either pegaptanib or usual care incurred lower lifetime total direct costs than those treated later. Sensitivity analysis showed that base-case incremental costs per QALY gained for pegaptanib versus usual care were relatively robust. Conclusions: For patients with subfoveal NV-AMD, treatment with pegaptanib should be started as early as possible to maximize the clinical and economic benefits.

Original languageEnglish (US)
Pages (from-to)563-574
Number of pages12
JournalValue in Health
Volume11
Issue number4
DOIs
StatePublished - Jul 2008

Fingerprint

Macular Degeneration
Visual Acuity
Cost-Benefit Analysis
costs
Costs and Cost Analysis
Quality-Adjusted Life Years
Therapeutics
Disease
comorbidity
economic model
Economic Models
rehabilitation
pegaptanib
incidence
Medicare
expert
Comorbidity
Rehabilitation
event
Economics

Keywords

  • Age-related macular degeneration
  • Cost-effectiveness
  • Markov model
  • Pegaptanib

ASJC Scopus subject areas

  • Nursing(all)
  • Health(social science)
  • Health Professions(all)

Cite this

Cost-effectiveness model for neovascular age-related macular degeneration : Comparing early and late treatment with pegaptanib sodium based on visual acuity. / Javitt, Jonathan C.; Zlateva, Gergana P.; Earnshaw, Stephanie R.; Pleil, Andreas M.; Graham, Christopher N.; Brogan, Anita J.; Shah, Sonali N.; Adamis, Anthony P.

In: Value in Health, Vol. 11, No. 4, 07.2008, p. 563-574.

Research output: Contribution to journalArticle

Javitt, Jonathan C. ; Zlateva, Gergana P. ; Earnshaw, Stephanie R. ; Pleil, Andreas M. ; Graham, Christopher N. ; Brogan, Anita J. ; Shah, Sonali N. ; Adamis, Anthony P. / Cost-effectiveness model for neovascular age-related macular degeneration : Comparing early and late treatment with pegaptanib sodium based on visual acuity. In: Value in Health. 2008 ; Vol. 11, No. 4. pp. 563-574.
@article{ef11937d25514b84bdc7f28661c4d6b9,
title = "Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity",
abstract = "Objective: To compare the cost-effectiveness of pegaptanib and usual care within three distinct cohorts of subfoveal neovascular age-related macular degeneration (NV-AMD) patients, that is, those with early, moderate, and late disease, using a comprehensive economic model. Methods: A Markov framework was used to model lifetime movement of a subfoveal NV-AMD cohort through health states based on visual acuity. The model takes a US payer perspective of patients over the age of 65 years. Clinical efficacy was based on published results for the 0.3 mg pegaptanib and usual care groups. Expert interviews were conducted to determine adverse event treatment patterns and vision rehabilitation resource use. Incidence and costs of comorbidities such as depression and fractures associated with the effects of declining visual acuity were based on our previously published analysis of Medicare data. Transition probabilities were derived from published clinical trial data for each 3-month cycle. Utilities were derived from published sources. Three runs of the model were conducted with cohorts of newly diagnosed patients. Patients were classified as having early, moderate, or late NV-AMD defined as visual acuity in the better-seeing eye of 20/40 to more than 20/80, 20/80 to more than 20/200, and 20/200 to more than 20/400, respectively. Costs and outcomes were discounted 3.0{\%} per annum. Results: Incremental costs per vision-year gained and per quality-adjusted life-year (QALY) gained for early NV-AMD patients were approximately one-third those of patients with late disease ($15,279 vs. $57,230 and $36,282 vs. $132,381, respectively). On average, patients treated early with either pegaptanib or usual care incurred lower lifetime total direct costs than those treated later. Sensitivity analysis showed that base-case incremental costs per QALY gained for pegaptanib versus usual care were relatively robust. Conclusions: For patients with subfoveal NV-AMD, treatment with pegaptanib should be started as early as possible to maximize the clinical and economic benefits.",
keywords = "Age-related macular degeneration, Cost-effectiveness, Markov model, Pegaptanib",
author = "Javitt, {Jonathan C.} and Zlateva, {Gergana P.} and Earnshaw, {Stephanie R.} and Pleil, {Andreas M.} and Graham, {Christopher N.} and Brogan, {Anita J.} and Shah, {Sonali N.} and Adamis, {Anthony P.}",
year = "2008",
month = "7",
doi = "10.1111/j.1524-4733.2007.00283.x",
language = "English (US)",
volume = "11",
pages = "563--574",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Cost-effectiveness model for neovascular age-related macular degeneration

T2 - Comparing early and late treatment with pegaptanib sodium based on visual acuity

AU - Javitt, Jonathan C.

AU - Zlateva, Gergana P.

AU - Earnshaw, Stephanie R.

AU - Pleil, Andreas M.

AU - Graham, Christopher N.

AU - Brogan, Anita J.

AU - Shah, Sonali N.

AU - Adamis, Anthony P.

PY - 2008/7

Y1 - 2008/7

N2 - Objective: To compare the cost-effectiveness of pegaptanib and usual care within three distinct cohorts of subfoveal neovascular age-related macular degeneration (NV-AMD) patients, that is, those with early, moderate, and late disease, using a comprehensive economic model. Methods: A Markov framework was used to model lifetime movement of a subfoveal NV-AMD cohort through health states based on visual acuity. The model takes a US payer perspective of patients over the age of 65 years. Clinical efficacy was based on published results for the 0.3 mg pegaptanib and usual care groups. Expert interviews were conducted to determine adverse event treatment patterns and vision rehabilitation resource use. Incidence and costs of comorbidities such as depression and fractures associated with the effects of declining visual acuity were based on our previously published analysis of Medicare data. Transition probabilities were derived from published clinical trial data for each 3-month cycle. Utilities were derived from published sources. Three runs of the model were conducted with cohorts of newly diagnosed patients. Patients were classified as having early, moderate, or late NV-AMD defined as visual acuity in the better-seeing eye of 20/40 to more than 20/80, 20/80 to more than 20/200, and 20/200 to more than 20/400, respectively. Costs and outcomes were discounted 3.0% per annum. Results: Incremental costs per vision-year gained and per quality-adjusted life-year (QALY) gained for early NV-AMD patients were approximately one-third those of patients with late disease ($15,279 vs. $57,230 and $36,282 vs. $132,381, respectively). On average, patients treated early with either pegaptanib or usual care incurred lower lifetime total direct costs than those treated later. Sensitivity analysis showed that base-case incremental costs per QALY gained for pegaptanib versus usual care were relatively robust. Conclusions: For patients with subfoveal NV-AMD, treatment with pegaptanib should be started as early as possible to maximize the clinical and economic benefits.

AB - Objective: To compare the cost-effectiveness of pegaptanib and usual care within three distinct cohorts of subfoveal neovascular age-related macular degeneration (NV-AMD) patients, that is, those with early, moderate, and late disease, using a comprehensive economic model. Methods: A Markov framework was used to model lifetime movement of a subfoveal NV-AMD cohort through health states based on visual acuity. The model takes a US payer perspective of patients over the age of 65 years. Clinical efficacy was based on published results for the 0.3 mg pegaptanib and usual care groups. Expert interviews were conducted to determine adverse event treatment patterns and vision rehabilitation resource use. Incidence and costs of comorbidities such as depression and fractures associated with the effects of declining visual acuity were based on our previously published analysis of Medicare data. Transition probabilities were derived from published clinical trial data for each 3-month cycle. Utilities were derived from published sources. Three runs of the model were conducted with cohorts of newly diagnosed patients. Patients were classified as having early, moderate, or late NV-AMD defined as visual acuity in the better-seeing eye of 20/40 to more than 20/80, 20/80 to more than 20/200, and 20/200 to more than 20/400, respectively. Costs and outcomes were discounted 3.0% per annum. Results: Incremental costs per vision-year gained and per quality-adjusted life-year (QALY) gained for early NV-AMD patients were approximately one-third those of patients with late disease ($15,279 vs. $57,230 and $36,282 vs. $132,381, respectively). On average, patients treated early with either pegaptanib or usual care incurred lower lifetime total direct costs than those treated later. Sensitivity analysis showed that base-case incremental costs per QALY gained for pegaptanib versus usual care were relatively robust. Conclusions: For patients with subfoveal NV-AMD, treatment with pegaptanib should be started as early as possible to maximize the clinical and economic benefits.

KW - Age-related macular degeneration

KW - Cost-effectiveness

KW - Markov model

KW - Pegaptanib

UR - http://www.scopus.com/inward/record.url?scp=47749151493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47749151493&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4733.2007.00283.x

DO - 10.1111/j.1524-4733.2007.00283.x

M3 - Article

C2 - 18179676

AN - SCOPUS:47749151493

VL - 11

SP - 563

EP - 574

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 4

ER -